Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

UK jabs deal to 'future-proof' immunisation

12/03/2021 | 01:21am EST

THE GOVERNMENT cut a deal with vaccine makers for millions of new jabs, as Pfizer's boss predicts that booster jabs are here to stay.

The deal for 114m Pfizer-BioNTech and Moderna jabs has secured doses for next year and 2023.

It seeks to "future proof" the UK's immunisation programme, health secretary Sajid Javid said in a statement yesterday.

With new variants of Covid-19 expected to keep emerging as long as there is room for the virus to spread, Pfizer boss Albert Bourla said annual vaccinations will be needed to maintain a "very high level of protection".

The latest strain of the virus, Omicron, had prompted the Government's deal for an undisclosed sum.

However, the World Health Organisation's (WHO) Covid-19 technical lead Maria Van Kerkhove has assured that early signs signal that a number of Omicron cases are "mild".

The Government has snagged around 54m Pfizer jabs and 60m of the Moderna vaccine.

The health secretary added: "This is a national mission and our best weapon to deal with this virus and its variants is to get jabs in arms - so when you are called forward, get the jab and get boosted."

It comes as the WHO looks to launch a global pact on preventing and controlling future pandemics.

The pact seeks to improve the hangups the world has had to manoeuvre during the pandemic, such as data sharing, genome sequencing of emerging variants, and vaccines.

The global health body intends to launch negotiations soon, with the deal expected to be ready by May 2024 and the first stage of talks to be held by the beginning of March next year.

"That may seem like a long process, and it is, but we should not be naive in thinking that reaching a global accord on pandemics will be easy," WHO director-general Tedros Adhanom Ghebreyesus said on Wednesday.

Ghebreyesus added that the number of countries recording Omicron cases is expected to grow - which is likely to have played a role in the Government's acquisition of more vaccines.

"This is what viruses do and what this virus will continue to do as long as we allow it to continue spreading," the WHO director explained.

(c) 2021 City A.M., source Newspaper

Stocks mentioned in the article
ChangeLast1st jan.
MODERNA, INC. -4.45% 160.07 Delayed Quote.-36.98%
PFIZER, INC. -2.33% 52.79 Delayed Quote.-10.60%
All news about PFIZER, INC.
04:29aTokyo hits record 10,000 COVID cases, Japan over 50,000 for first time
04:29aTokyo hits record 10,000 COVID cases, Japan over 50,000 for first time
01/21Pzifer, OPKO Health Evaluating FDA's Complete Response Letter on Growth Hormone Replace..
01/21Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for ..
01/21Pfizer Inc. and OPKO Health, Inc. Provide Update on the Biologics License Application f..
01/21Moderna's Valuation Has Come 'Back to Earth,' Become More Reasonable, BofA Securities S..
01/21Boosters provide 'added protection' against Omicron -CDC
01/21Small children getting less sick from Omicron; Genetic mutation protects against severe..
01/21Booster shots needed against omicron, CDC studies show
01/21U.S. studies highlight the need for COVID boosters to fight Omicron
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2021 81 972 M - -
Net income 2021 22 216 M - -
Net Debt 2021 27 397 M - -
P/E ratio 2021 13,8x
Yield 2021 3,00%
Capitalization 296 B 296 B -
EV / Sales 2021 3,95x
EV / Sales 2022 3,12x
Nbr of Employees 78 500
Free-Float 59,3%
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | PFE | US7170811035 | MarketScreener
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 52,79 $
Average target price 57,79 $
Spread / Average Target 9,46%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Susan Silbermann President & General Manager-Pfizer Vaccines
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-10.60%296 303
JOHNSON & JOHNSON-3.40%434 036
ROCHE HOLDING AG-4.87%319 830
ABBVIE INC.-2.53%233 325
NOVO NORDISK A/S-14.11%219 146